Entity

Time filter

Source Type


Sun G.,Key Laboratory of Transplant Engineering and Immunology of Health | Zhou Y.,Key Laboratory of Transplant Engineering and Immunology of Health | Li H.,Key Laboratory of Transplant Engineering and Immunology of Health | Guo Y.,Key Laboratory of Transplant Engineering and Immunology of Health | And 10 more authors.
Journal of Biomedical Science | Year: 2013

Background: Hypoxia-inducible factor-1 alpha (HIF-1) is one of the key regulators of hypoxia/ischemia. MicroRNA-494 (miR-494) had cardioprotective effects against ischemia/reperfusion (I/R)-induced injury, but its functional relationship with HIF-1 was unknown. This study was undertaken to determine if miR-494 was involved in the induction of HIF-1. Results: Quantitative RT-PCR showed that miR-494 was up-regulated to peak after 4 hours of hypoxia in human liver cell line L02. To investigate the role of miR-494, cells were transfected with miR-494 mimic or miR-negative control, followed by incubation under normoxia or hypoxia. Our results indicated that overexpression of miR-494 significantly induced the expression of p-Akt, HIF-1 and HO-1 determined by qRT-PCR and western blot under normoxia and hypoxia, compared to negative control (p < 0.05). While LY294002 treatment markedly abolished miR-494-inducing Akt activation, HIF-1 and HO-1 increase under both normoxic and hypoxic conditions (p < 0.05). Moreover, apoptosis detection using Annexin V indicated that overexpression of miR-494 significantly decreased hypoxia-induced apoptosis in L02 cells, compared to control (p < 0.05). MiR-494 overexpression also decreased caspase-3/7 activity by 1.27-fold under hypoxia in L02 cells. Conclusions: Overexpression of miR-494 upregulated HIF-1 expression through activating PI3K/Akt pathway under both normoxia and hypoxia, and had protective effects against hypoxia-induced apoptosis in L02 cells. Thus, these findings suggested that miR-494 might be a target of therapy for hepatic hypoxia/ischemia injury. © 2013Sun et al.; licensee BioMed Central Ltd.

Discover hidden collaborations